The first quarter of the year has gone according to plan for the Danish biotech firm Genmab.
Research and development (R&D) activities have been especially busy, and the firm has posted a sizeable amount of money into the continued expansion of the organization.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Clinical Supply Coordinator - Klifo 
Senior Manager, IT QA - Genmab 
Senior Clinical Development Scientist/Physician - Lundbeck 
Drug Safety Advisor - ALK 
Associate Formulation Scientist, Oral Formulation Research - Novo Nordisk 
Project Assistant, Translational medicine - Y-mAbs Therapeutics 
Regulatory affairs life cycle specialist 
(Senior) Regulatory Science Specialist - IWA Consulting